Tryptamine Therapeutics Advances with TRP-8803 Breakthrough

Tryptamine Therapeutics (AU:TYP) has released an update.

Tryptamine Therapeutics has announced successful completion of its Phase 1b trial for TRP-8803, an innovative IV-infused psilocin formulation. The study confirmed the safety and efficacy of TRP-8803 in achieving controlled psychedelic states with faster onset compared to oral psilocybin. This development paves the way for Phase 2 trials, potentially offering new therapeutic options for neuroplastic treatment.

For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.